Cover Image

Real-life experience in the treatment of intrahepatic cholangiocarcinoma by 90Y radioembolization: a multicenter retrospective study

Limited treatment options in patients with intrahepatic cholangiocarcinoma (iCCA) demand the introduction of new, catheter-based treatment options. Especially, 90Y radioembolization may expand therapeutic abilities beyond surgery or chemotherapy. Therefore, the purpose of this study was to identify...

Full description

Saved in:
Bibliographic Details
Main Authors: Schaarschmidt, Benedikt Michael Sebastian (Author) , Kloeckner, Roman (Author) , Dertnig, Thomas (Author) , Demircioglu, Aydin (Author) , Müller, Lukas (Author) , Auer, Timo Alexander (Author) , Santos, Daniel Pinto dos (Author) , Wagner, Verena (Author) , Miederer, Matthias (Author) , Gebauer, Bernhard (Author) , Radunz, Sonia (Author) , Kasper, Stefan (Author) , Weber, Manuel (Author) , Theysohn, Jens (Author)
Format: Article (Journal)
Language:English
Published: April 1, 2023
In: Journal of nuclear medicine
Year: 2023, Volume: 64, Issue: 4, Pages: 529-535
ISSN:2159-662X
DOI:10.2967/jnumed.122.264598
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.2967/jnumed.122.264598
Verlag, lizenzpflichtig, Volltext: https://jnm.snmjournals.org/content/64/4/529
Get full text
Author Notes:Benedikt M. Schaarschmidt, Roman Kloeckner, Thomas Dertnig, Aydin Demircioglu, Lukas Müller, Timo Alexander Auer, Daniel Pinto dos Santos, Verena Steinle, Matthias Miederer, Bernhard Gebauer, Sonia Radunz, Stefan Kasper, Manuel Weber and Jens Theysohn
Description
Summary:Limited treatment options in patients with intrahepatic cholangiocarcinoma (iCCA) demand the introduction of new, catheter-based treatment options. Especially, 90Y radioembolization may expand therapeutic abilities beyond surgery or chemotherapy. Therefore, the purpose of this study was to identify factors associated with an improved median overall survival (mOS) in iCCA patients receiving radioembolization in a retrospective study at 5 major tertiary-care centers. Methods: In total, 138 radioembolizations in 128 patients with iCCA (female, 47.7%; male, 52.3%; mean age ± SD, 61.1 ± 13.4 y) were analyzed. Clinical data, imaging characteristics, and radioembolization reports, as well as data from RECIST, version 1.1, analysis performed 3, 6, and 12 mo after radioembolization, were collected. mOS was compared among different subgroups using Kaplan–Meier curves and the log-rank test. Results: Radioembolization was performed as first-line treatment in 25.4%, as second-line treatment in 38.4%, and as salvage treatment in 36.2%. In patients receiving first-line, second-line, and salvage radioembolization, the disease control rate was 68.6%, 52.8%, and 54.0% after 3 mo; 31.4%, 15.1%, and 12.0% after 6 mo; and 17.1%, 5.7%, and 6.0% after 1 y, respectively. In patients receiving radioembolization as first-line, second-line, and salvage treatment, mOS was 12.0 mo (95% CI, 7.6–23.4 mo), 11.8 mo (95% CI, 9.1–16.6 mo), and 8.4 mo (95% CI, 6.3–12.7 mo), respectively. No significant differences among the 3 groups were observed (P = 0.15). Hepatic tumor burden did not significantly influence mOS (P = 0.12). Conclusion: Especially in advanced iCCA, second-line and salvage radioembolization may be important treatment options. In addition to ongoing studies investigating the role of radioembolization as first-line treatment, the role of radioembolization in the later treatment stages of the disease demands further attention.
Item Description:Online veröffentlicht: 3. November 2022
Im Titel ist die Zahl 90 hochgestellt
Gesehen am 15.08.2023
Physical Description:Online Resource
ISSN:2159-662X
DOI:10.2967/jnumed.122.264598

Similar Items